Hepatitis C Viral Kinetics. The Past, Present, and Future

Clinics in Liver Disease

Volumn 17, Issue 1, 2013, Pages 13-26

  Chatterjee, Anushree ^a,b   Smith, Patrick F ^c   Perelson, Alan S ^a  

^a LOS ALAMOS NATIONAL LABORATORY   (United States)

^b CENTER FOR NONLINEAR STUDIES   (United States)

^c Pharma Research and Early Development   (United States)

Author keywords

Direct acting antiviral agents; Hepatitis C virus; Mathematical modeling; Protease inhibitors; Viral kinetics

Indexed keywords

BMS 79002; CILUPREVIR; DACLATASVIR; INTERFERON; MERICITABINE; PEGINTERFERON ALPHA2A; RIBAVIRIN; SILIBININ; TELAPREVIR; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA;

ANTIVIRAL THERAPY; CLINICAL EFFECTIVENESS; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG MEGADOSE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MATHEMATICAL MODEL; MONOTHERAPY; NONHUMAN; REVIEW; SINGLE DRUG DOSE; TREATMENT DURATION; VIRUS GENE; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DEOXYCYTIDINE; HEPACIVIRUS; HEPATITIS C; HUMANS; IMIDAZOLES; MODELS, BIOLOGICAL; OLIGOPEPTIDES; PROTEASE INHIBITORS; SILYMARIN;

EID: 84870014667     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2012.09.003     Document Type: Review

References (70)

1. Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology 2002, 36(5):S21-S29.
2. Lindenbach B.D., Rice C.M. Unravelling hepatitis C virus replication from genome to function. Nature 2005, 436(7053):933-938.
3. Davis G.L., Albright J.E., Cook S.F., et al. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003, 9(4):331-338.
4. McHutchison J.G., Lawitz E.J., Shiffman M.L., et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009, 361(6):580-593.
5. Abdelmalek M.F., Firpi R.J., Soldevila-Pico C., et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2004, 10(2):199-207.
6. TenCate V., Sainz B.J., Cotler S.J., et al. Potential treatment options and future research to increase hepatitis C virus treatment response rate. Hepat Med 2010, 2:125-145.
7. Ciesek S., von Hahn T., Manns M.P. Second-wave protease inhibitors: choosing an heir. Clin Liver Dis 2011, 15(3):597-609.
8. Hézode C., Forestier N., Dusheiko G., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009, 360(18):1839-1850.
9. Pawlotsky J.M. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011, 53(5):1742-1751.
10. Thompson A., Patel K., Tillman H., et al. Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges. J Hepatol 2009, 50(1):184-194.
11. De Meyer S.M., Dierynck I., Ghys A., et al. Similar incidence of virological failure and emergence of resistance with or without a lead-in: results of a telaprevir Phase 3 study in patients who did not achieve SVR with prior Peg-IFN/RBV treatment. Antivir Ther 2011, 16(4):A25.
12. Hiraga N., Imamura M., Abe H., et al. Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo. Hepatology 2011, 54(3):781-788.
13. Kieffer T.L., Sarrazin C., Miller J.S., et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007, 46(3):631-639.
14. Malcolm B.A., Liu R., Lahser F., et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 2006, 50(3):1013-1020.
15. Rong L., Perelson A.S. Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling. Crit Rev Immunol 2010, 30(2):131-148.
16. Bartels D.J., Zhou Y., Zhang E.Z., et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3/4A protease inhibitors in treatment-naive subjects. J Infect Dis 2008, 198(6):800-807.
17. Lin C., Gates C.A., Rao B.G., et al. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem 2005, 280(44):36784-36791.
18. Nettles R.E., Gao M., Bifano M., et al. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 2011, 54(6):1956-1965.
19. Poordad F., McCone J., Bacon B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364(13):1195-1206.
20. Neumann A.U., Lam N.P., Dahari H., et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998, 282(5386):103-107.
21. Perelson A.S., Neumann A.U., Markowitz M., et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271(5255):1582-1586.
22. Dixit N.M., Layden-Almer J.E., Layden T.J., et al. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004, 432(7019):922-924.
23. Perelson A.S., Essunger P., Cao Y.Z., et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997, 387(6629):188-191.
24. Dahari H., Lo A., Ribeiro R.M., et al. Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy. J Theor Biol 2007, 247(2):371-381.
25. Shudo E., Ribeiro R.M., Perelson A.S. Modeling HCV kinetics under therapy using PK and PD information. Expert Opin Drug Metab Toxicol 2009, 5(3):321-332.
26. Dahari H., Guedj J., Perelson A., et al. Hepatitis C viral kinetics in the era of direct acting antiviral agents and interleukin-28B. Curr Hepat Rep 2011, 10(3):214-227.
27. Guedj J., Dahari H., Pohl R.T., et al. Understanding silibinin's modes of action against HCV using viral kinetic modeling. J Hepatol 2012, 56:1019-1024.
28. Ribeiro R.M., Layden-Almer J., Powers K.A., et al. Dynamics of alanine aminotransferase during hepatitis C virus treatment. Hepatology 2003, 38(2):509-517.
29. Guedj J., Neumann A.U. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics. J Theor Biol 2010, 267(3):330-340.
30. Guedj H., Guedj J., Negro F., et al. The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1 infected patients treated with PEG-IFN-alfa-2a and ribavirin. J Viral Hepat 2012, 19(7):1365-2893.
31. Welling P.G. Pharmacokinetics: processes and mathematics. ACS (American Chemical Society) Monograph 1986, 185. XIV+290P.
32. Talal A.H., Ribeiro R.M., Powers K.A., et al. Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Hepatology 2006, 43(5):943-953.
33. Guedj J., Rong L., Dahari H., et al. A perspective on modelling hepatitis C virus infection. J Viral Hepat 2010, 17(12):825-833.
34. Adiwijaya B.S., Hare B., Caron P.R., et al. Rapid decrease of wild-type hepatitis C virus on telaprevir treatment. Antivir Ther 2009, 14(4):591-595.
35. Hinrichsen H., Benhamou Y., Wedemeyer H., et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 2004, 127(5):1347-1355.
36. Guedj J., Perelson A.S. Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology 2011, 53(6):1801-1808.
37. Rong L., Dahari H., Ribeiro R.M., et al. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2010, 2(30):30ra32.
38. Tong X., Bogen S., Chase R., et al. Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Res 2008, 77(3):177-185.
39. Ribeiro R.M., Li H., Wang S., et al. Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog 2012, 8(8):e1002881.
40. Sarrazin C., Kieffer T.L., Bartels D., et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007, 132(5):1767-1777.
41. Kieffer T.L., De Meyer S., Bartels D.J., et al. Clinical virology findings from treatment-naive and treatment-experienced genotype 1 HCV patients receiving telaprevir/peginterferon/ribavirin in Phase 3 clinical trials. Antivir Ther 2011, 16(4):A27.
42. Kieffer T., Zhou Y., Zhang E., et al. Evaluation of viral variants during a Phase 2 study (PROVE2) of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive HCV genotype I-infected patients. Hepatology 2007, 46(4):862A.
43. Adiwijaya B.S., Herrmann E., Hare B., et al. A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants. PLoS Comput Biol 2010, 6(4):e1000745.
44. Domingo E. Biological significance of viral quasispecies. Viral Hepatitis Rev 1996, 2:247-261.
45. Rong L., Ribeiro R.M., Perelson A.S. Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor. Bull Math Biol 2012, 74:1789-1817.
46. Reddy R., Rodriguez-Torres M., Gane E., et al. Antiviral activity, pharmacokinetics, safety and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. Hepatology 2007, 46(4):862A-863A.
47. Guedj J., Dahari H., Shudo E., et al. Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Hepatology 2012, 55:1030-1037.
48. Gao M., Nettles R.E., Belema M., et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010, 465(7294):96-108.
49. Ramratnam B., Bonhoeffer S., Binley J., et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 1999, 354(9192):1782-1785.
50. Ahmed-Belkacem A., Ahnou N., Barbotte L., et al. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology 2010, 138(3):1112-1122.
51. Wagoner J., Morishima C., Graf T.N., et al. Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation. PLoS One 2011, 6(1):e16464.
52. Wagoner J., Negash A., Kane O.J., et al. Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology 2010, 51(6):1912-1921.
53. Ferenci P., Scherzer T.M., Kerschner H., et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 2008, 135(5):1561-1567.
54. Polyak S.J., Morishima C., Shuhart M.C., et al. Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappa B signaling, and HCV infection by standardized silymarin. Gastroenterology 2007, 132(5):1925-1936.
55. Snoeck E., Chanu P., Lavielle M., et al. A comprehensive hepatitis C viral kinetic model explaining cure. Clin Pharmacol Ther 2010, 87(6):706-713.
56. Benson N., de Jongh J., Duckworth J.D., et al. Pharmacokinetic-pharmacodynamic modeling of alpha interferon response induced by a Toll-like 7 receptor agonist in mice. Antimicrob Agents Chemother 2010, 54(3):1179-1185.
57. Jones H.M., Chan P.L., van der Graaf P.H., et al. Use of modelling and simulation techniques to support decision making on the progression of PF-04878691, a TLR7 agonist being developed for hepatitis C. Br J Clin Pharmacol 2012, 73(1):77-92.
58. Reddy M.B., Morcos P.N., Le Pogam S., et al. Pharmacokinetic/pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitors. Antimicrob Agents Chemother 2012, 56(6):3144-3156.
59. Gane E.J., Roberts S.K., Stedman C.A., et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010, 376(9751):1467-1475.
60. Forestier N., Larrey D., Guyader D., et al. Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study. J Hepatol 2011, 54(6):1130-1136.
61. Gane E. Future hepatitis C virus treatment: interferon-sparing combinations. Liver Int 2011, 31:62-67.
62. Dahari H., Ribeiro R.M., Rice C.M., et al. Mathematical modeling of subgenomic hepatitis C virus replication in Huh-7 cells. J Virol 2007, 81(2):750-760.
63. Yang F., Robotham J.M., Nelson H.B., et al. Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. J Virol 2008, 82(11):5269-5278.
64. Lagging M., Romero A.I., Westin J., et al. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology 2006, 44(6):1617-1625.
65. Thomas D.L., Thio C.L., Martin M.P., et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461(7265):798-801.
66. Helle F., Wychowski C., Vu-Dac N., et al. Cyanovirin-N Inhibits hepatitis C virus entry by binding to envelope protein glycans. J Biol Chem 2006, 281(35):25177-25183.
67. Lawitz E., Rodriguez-Torres M., DeMico M., et al. Antiviral activity of ANA598, a potent non-nucleoside polymerase inhibitor, in chronic hepatitis C patients. J Hepatol 2009, 50:S384.
68. Larrey D., Lohse A.W., de Ledinghen V., et al. Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. J Hepatol 2012, 57:39-46.
69. Ray A.S., Feng J.Y., Wang T., et al. 1233 GS-6620: A liver targeted nucleotide prodrug with potent pan-genotype anti-hepatitis C virus activity in vitro. J Hepatol 2011, 54:S487.
70. Coelmont L., Hanoulle X., Chatterji U., et al. DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a Cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One 2010, 5(10):e13687.